Gene644
BLVRA: biliverdin reductase A
Cite this record
ConductScience Library. BLVRA: biliverdin reductase A. Genes, record 644. Release gene-search-2026-11-13-0.2.1, 13 Nov 2026. https://conductscience.org/library/genes/644
- Sources
- 13 sources
- Release
- gene-search-2026-11-13-0.2.1
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P53004 | Biliverdin reductase A | 296 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents90
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 20260193644 A1 | 2026-07-09 | 2077 | P53004 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39009 | P53004 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39010 | P53004 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2491 | P53004 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2077 | P53004 | Espacenet |
| US 20250320254 A1 | 2025-10-16 | 2491 | P53004 | Espacenet |
| US 20250283879 A1 | 2025-09-11 | 444 | P53004 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 2077 | P53004 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2491 | P53004 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 9120 | P53004 | Espacenet |
NIH grants513
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BLVRA papers | Newest fiscal year |
|---|---|---|---|
| P30ES001247 | Environmental Agents as Modulators of Disease Processes | 5 | 2025 |
| P20GM121334 | Mississippi Center of Excellence in Perinatal Research, Phase 2 | 4 | 2025 |
| T32HL105324 | Hypertension and Cardiorenal Research Training Program | 4 | 2025 |
| P30CA177558 | University of Kentucky Markey Cancer Center – Cancer Center Support Grant | 3 | 2025 |
| P30ES006694 | Southwest Environmental Health Sciences Center | 3 | 2025 |
| R01AG071512 | Neuroprotective actions of cystathionine g-lyase through gasotransmitter hydrogen sulfide signaling | 3 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 2 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 2 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 2 | 2025 |
| P42ES004940 | The DUST Center: Hazardous Dust in Drylands - Exposure, Health Impacts, and Mitigation | 2 | 2025 |
Source NIH's project files
Papers695
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Bilirubin and the Yellow Players in Ferroptosis: A Delicate Balance in Human Health and Disease, with a Focus on the Liver, Cardiovascular System, and Brain. | Biomolecules | 2026 | 42793203 | PubTator, text mining | PubMed |
| Editorial Expression of Concern: Biliverdin reductase-A attenuated GMH induced inflammatory response in the spleen by inhibiting toll-like receptor-4 through eNOS/NO pathway. | J Neuroinflammation | 2026 | 42661195 | PubTator, text mining | PubMed |
| Microbiome-derived cancer: the catabolism of bilirubin to urobilin in the liver-gut axis and its consequences. | Gastroenterol Rep (Oxf) | 2026 | 42404236 | PubTator, text mining | PubMed |
| Ferroptosis is a Physiologic Vulnerability of Iron-Recycling Macrophages. | bioRxiv | 2026 | 42395532 | PubTator, text mining | PubMed |
| From mechanism to clinic: a panoramic perspective on targeting HMOX1 to overcome drug resistance. | J Cancer Res Clin Oncol | 2026 | 41786997 | PubTator, text mining | PubMed |
| Expert Consensus on the Diagnosis and Management of Inherited Hyperbilirubinemia (2025). | J Clin Transl Hepatol | 2026 | 41659992 | PubTator, text mining | PubMed |
| Overexpression of biliverdin reductase A leads to ROS-independent sensitization of ovarian adenocarcinoma cells to gemcitabine. | Exp Cell Res | 2026 | 41581642 | PubTator, text mining | PubMed |
| Biliverdin reductase-A is a key modulator in insulin signaling and metabolism. | Trends Endocrinol Metab | 2026 | 40912934 | PubTator, text mining | PubMed |
| Role of biliverdin reductase, a heme degradation pathway enzyme, in the development of vasospasm after subarachnoid hemorrhage. | J Neurointerv Surg | 2026 | 40404300 | PubTator, text mining | PubMed |
| Systematic druggable genome-wide mendelian randomization identifies therapeutic targets for childhood asthma. | Medicine (Baltimore) | 2025 | 41398767 | PubTator, text mining | PubMed |
None in this release
- Drugs
- Trials
Sources 13
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
- USPTO's sequence listingsPublic domain in the US. Source: United States Patent and Trademark Office, www.uspto.gov
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
- USPTO's sequence listingsUSPTO's sequence listings of patents and published applications, from its bulk data files. No license named for the files. USPTO's terms say "most government-produced materials appearing on this website are not subject to copyright restrictions within the United States and are therefore in the public domain", and ask that USPTO be given appropriate acknowledgement ("Source: United States Patent and Trademark Office, www.uspto.gov"). USPTO does not endorse ConductScience or this release. Read on 12 Nov 2026 at https://www.uspto.gov/terms-use-uspto-websites
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
Source: United States Patent and Trademark Office, www.uspto.gov. USPTO does not endorse ConductScience or this database.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/644
GET https://conductscience.org/api/genes/v1/644/patents?page=2